Full View

Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma

C Grommes, SS Tang, J Wolfe, TJ Kaley… - Blood, The Journal …, 2019 - ashpublications.org
Ibrutinib is a first-in-class inhibitor of Bruton tyrosine kinase (BTK) and has shown single-
agent activity in recurrent/refractory central nervous system (CNS) lymphoma. Clinical …
被引用次数：225 相关文章
[HTML] sciencedirect.com

[HTML][HTML] Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma

C Grommes, SS Tang, J Wolfe, TJ Kaley, M Daras… - Blood, 2019 - Elsevier
Ibrutinib is a first-in-class inhibitor of Bruton tyrosine kinase (BTK) and has shown single-
agent activity in recurrent/refractory central nervous system (CNS) lymphoma. Clinical …

Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma

C Grommes, SS Tang, J Wolfe, TJ Kaley, M Daras… - Blood, 2019 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Ibrutinib is a first-in-class inhibitor of Bruton
tyrosine kinase (BTK) and has shown single-agent activity in recurrent/refractory central …
[HTML] nih.gov

[HTML][HTML] Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma

C Grommes, SS Tang, J Wolfe, TJ Kaley, M Daras… - Blood, 2019 - ncbi.nlm.nih.gov
Ibrutinib is a first-in-class inhibitor of Bruton tyrosine kinase (BTK) and has shown single-
agent activity in recurrent/refractory central nervous system (CNS) lymphoma. Clinical …

Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma

C Grommes, SS Tang, J Wolfe, TJ Kaley, M Daras… - …, 2019 - pubmed.ncbi.nlm.nih.gov
Ibrutinib is a first-in-class inhibitor of Bruton tyrosine kinase (BTK) and has shown single-
agent activity in recurrent/refractory central nervous system (CNS) lymphoma. Clinical …

Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.

C Grommes, SS Tang, J Wolfe, TJ Kaley, M Daras… - Blood, 2018 - europepmc.org
Ibrutinib is a first-in-class inhibitor of Bruton tyrosine kinase (BTK) and has shown single-
agent activity in recurrent/refractory central nervous system (CNS) lymphoma. Clinical …

Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.

C Grommes, SS Tang, J Wolfe, TJ Kaley, M Daras… - Blood, 2018 - europepmc.org
Ibrutinib is a first-in-class inhibitor of Bruton tyrosine kinase (BTK) and has shown single-
agent activity in recurrent/refractory central nervous system (CNS) lymphoma. Clinical …